Announced details
Improving efficiency in clinical trial operations; raising public and healthcare professional awareness of, and providing information on, clinical trials
Mitsubishi Research Institute, Inc. hosts the Japan Clinical Trial Transformation (CTX) Study Group
18 companies, 5 medical institutions (including universities), and 14 academic researchers participated
In this announcement the company addresses none of Contract Value / Offering price / Impact on Business Performance.
Institute for Pharmaceutical Industry Policy position paper (24 May 2024 edition); Cabinet Office, Basic Policy on Economic and Fiscal Management and Reform (Basic Policy) 2026
| Item | Details |
|---|---|
| Names of Products / Services Covered | Third-Term Recommendation Papers of the Japan Clinical Trial Transformation (CTX) Study Group (Recommendations for Accelerating Efficiency at Clinical Trial Sites; Recommendations for Raising Public and Healthcare Professional Awareness of, and Providing Information on, Clinical Trials) |
| Relationship with the Company | Mitsubishi Research Institute, Inc. hosts the Japan Clinical Trial Transformation (CTX) Study Group |
| Launch date | 10 September 2026 (recommendations published; actual) |
| Applicable area | Improving efficiency in clinical trial operations; raising public and healthcare professional awareness of, and providing information on, clinical trials |
| Location scale | 18 companies, 5 medical institutions (including universities), and 14 academic researchers participated |
| Source | Institute for Pharmaceutical Industry Policy position paper (24 May 2024 edition); Cabinet Office, Basic Policy on Economic and Fiscal Management and Reform (Basic Policy) 2026 |
Items this document does not state (12)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Because improvements to Japan’s domestic clinical trial environment are considered necessary for Japan to be selected for international joint clinical trials, thereby eliminating drug loss and ensuring access to new drugs. In addition, discussions during the second term identified practices that hinder clinical trial efficiency and the limited number of people who have access to clinical trial information as issues.